| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
145,981,000 |
| Market
Cap: |
322.62(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $2.88 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
25,516 |
25,516 |
25,516 |
| Total Sell Value |
$0 |
$30,379 |
$30,379 |
$30,379 |
| Total People Sold |
0 |
3 |
3 |
3 |
| Total Sell Transactions |
0 |
3 |
3 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hagan Joseph P |
President and CEO |
• • – |
2019-05-07 |
4 |
B |
$1.08 |
$35,850 |
D/D |
33,194 |
64,542 |
2.81 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2019-05-07 |
4 |
B |
$1.08 |
$400,000 |
D/D |
370,370 |
1,189,872 |
2.39 |
- |
|
| Witz Pascale |
Director |
– • – |
2019-05-07 |
4 |
B |
$1.08 |
$32,000 |
D/D |
29,630 |
37,849 |
2.39 |
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2019-04-01 |
4 |
AS |
$0.98 |
$5,731 |
D/D |
(5,842) |
31,348 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2019-04-01 |
4 |
AS |
$0.98 |
$2,659 |
D/D |
(2,710) |
6,287 |
|
- |
|
| Chevallard Daniel R. |
Chief Financial Officer |
• – – |
2019-04-01 |
4 |
AS |
$0.98 |
$3,192 |
D/D |
(3,253) |
9,372 |
|
- |
|
| Wright Timothy Michael |
Chief R & D Officer |
• – – |
2019-02-05 |
4 |
A |
$0.95 |
$38,000 |
D/D |
40,000 |
62,893 |
|
- |
|
| Hagan Joseph P |
President and CEO |
• • – |
2019-02-05 |
4 |
A |
$0.95 |
$61,750 |
D/D |
65,000 |
84,148 |
|
- |
|
| Aker Christopher Ray |
Sr. VP & General Counsel |
• – – |
2019-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
27,747 |
|
- |
|
| Chevallard Daniel R. |
Chief Financial Officer |
• – – |
2019-02-05 |
4 |
A |
$0.95 |
$28,500 |
D/D |
30,000 |
34,578 |
|
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-12-28 |
4 |
B |
$1.09 |
$54,570 |
D/D |
50,000 |
835,073 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-12-27 |
4 |
B |
$1.04 |
$27,460 |
D/D |
26,401 |
785,073 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-12-26 |
4 |
B |
$0.95 |
$85,878 |
D/D |
90,000 |
758,672 |
2.39 |
- |
|
| Collier Kathryn J |
Director |
– • – |
2018-11-16 |
4 |
B |
$1.41 |
$10,011 |
D/D |
7,100 |
27,596 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-11-16 |
4 |
B |
$1.38 |
$415,470 |
D/D |
300,000 |
668,672 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-11-15 |
4 |
B |
$1.33 |
$265,080 |
D/D |
200,000 |
368,672 |
2.39 |
- |
|
| Papadopoulos Stelios |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
20,910 |
168,672 |
|
- |
|
| Baltimore David |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
40,339 |
44,131 |
|
- |
|
| Rosen Hugh |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
19,245 |
22,756 |
|
- |
|
| Witz Pascale |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
15,833 |
19,625 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
I/I |
23,258 |
79,672 |
|
- |
|
| Collier Kathryn J |
Director |
– • – |
2018-11-12 |
4 |
A |
$0.00 |
$0 |
D/D |
16,874 |
20,496 |
|
- |
|
| Collier Kathryn J |
Director |
– • – |
2018-06-05 |
4 |
A |
$0.74 |
$5,694 |
D/D |
7,695 |
7,695 |
|
- |
|
| Collier Kathryn J |
Director |
– • – |
2018-04-14 |
4 |
A |
$0.64 |
$38,550 |
D/D |
60,234 |
60,234 |
|
- |
|
| Rosen Hugh |
Director |
– • – |
2017-12-04 |
4 |
A |
$0.89 |
$49,999 |
D/D |
56,179 |
56,179 |
|
- |
|
341 Records found
|
|
Page 4 of 14 |
|
|
0.04 (1.78%) 
